Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

B. Riley Securities Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $20

Author: Benzinga Newsdesk | August 26, 2025 05:22am
B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $20.

Posted In: ACTU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist